Newron Pharmaceuticals Ratios and Metrics

Market cap in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 12, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	372	154	82	25	23	32
Market Cap Growth	128.91%	86.40%	231.73%	6.01%	-26.26%	-64.05%
Enterprise Value	381	185	110	39	28	19
Last Close Price	18.82	7.92	4.63	1.19	1.29	1.78
PE Ratio	17.14	11.72	-	-	-	-
PS Ratio	7.25	3.61	10.48	4.59	4.84	6.74
PB Ratio	274.44	127.32	-3.17	-1.99	8.98	2.06
P/TBV Ratio	274.61	127.32	-	-	8.98	2.06
EV/Sales Ratio	7.13	4.34	13.95	7.26	5.77	4.13
EV/EBITDA Ratio	12.06	8.52	-	-	-	-
EV/EBIT Ratio	12.13	8.53	-	-	-	-
Debt / Equity Ratio	33.23	34.62	-1.62	-3.25	13.87	1.53
Debt / EBITDA Ratio	1.49	1.91	-	-	-	-
Net Debt / Equity Ratio	5.92	27.88	-1.20	-1.63	2.73	-0.28
Net Debt / EBITDA Ratio	0.27	1.55	-3.12	-1.72	-0.69	0.27
Net Debt / FCF Ratio	0.38	-2.31	-3.53	-2.06	-0.74	0.31
Asset Turnover	1.39	1.15	0.29	0.14	0.11	0.09
Quick Ratio	1.40	2.42	0.62	5.50	10.58	5.50
Current Ratio	1.51	2.60	0.68	5.65	10.79	5.50
Return on Equity (ROE)	-	-	-	-	-146.43%	-77.71%
Return on Assets (ROA)	50.97%	36.44%	-23.05%	-18.96%	-15.19%	-20.26%
Return on Invested Capital (ROIC)	263.58%	80.74%	-157.51%	-130.08%	-103.26%	-134.50%
Return on Capital Employed (ROCE)	165.20%	64.80%	380.00%	-41.40%	-26.40%	-40.80%
Earnings Yield	5.83%	8.54%	-17.09%	-62.50%	-53.44%	-59.23%
FCF Yield	5.65%	-9.50%	-10.70%	-39.69%	-41.12%	-44.07%
Buyback Yield / Dilution	-16.86%	-15.30%	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.